Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients (RESCUEII)
Continuous Glucose Monitoring by Subcutaneous Measurement Compared to Frequent Point of Care Measurement by Accu Chek in Critically Ill Patients; a Randomized Controlled Trial (RESCUEII)
調査の概要
詳細な説明
Most patients admitted to the ICU are treated with intensive insulin therapy, according to a locally developed glucose treatment protocol. The use of a continuous glucose monitoring in critically ill patients could have the following advantages:
- Better insight in the alterations of the blood glucose levels
- Early detection of hypoglycemia's or hyperglycaemia's, and subsequently more stable glycemic levels.
- Fewer blood samples
- Decreased workload for the nursing staff
In this study, patients will be randomized in: 1. The Freestyle group or 2. The AccuChek Group.
Patients in both groups will receive a Freestyle Navigator device, which will stay on the patient up to 5 days, or until discharge from the ICU.
The medical treatment of both study groups will be equal, except for the frequency of the glucose level measurements and the resulting adjustments according to the treatment protocol. In the Freestyle group extra glucose level measurements will be made in response to alarms from the device.
In both groups, every 4 hours blood glucose values will be obtained using a blood gas analyzer (BGA). When a control measurement by BGA results in a glucose level of <2.2 or >25 mmol/l, the value will be transmitted to the Patient Data Management System (PDMS) and gives an alarm. Otherwise, the value will be blinded in the PDMS.
Freestyle Navigator data will be downloaded from the device. Blood glucose values obtained in the course of usual care will be compared with time-matched Freestyle Navigator values to assess device accuracy.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Amsterdam、オランダ
- Onze Lieve Vrouwe Gasthuis
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- ICU-patients > 18 years
- Expected length of stay on the ICU > 24 hours
- Indication for glucose regulation with insulin (according to the current glucose treatment protocol)
- Availability of the Freestyle Navigator
Exclusion Criteria:
- Participation in another trial subject to the WMO
- Lack of informed consent
- Contraindication for the use of the Accu Chek (for example peritoneal dialysis, Ht <0,20 of > 0,65; paracetamol intoxication)
- Contraindication for placement of the subcutaneous glucose sensor
- Participation in this trial during previous ICU admittance
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：診断
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Freestyle group
Glucose levels are being monitored with the Freestyle Navigator up to 5 days, or until discharge from the ICU
|
Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
他の名前：
|
|
アクティブコンパレータ：AccuChek group
Glucose levels are being measured by the AccuChek.
Patients also get a Freestyle Navigator, which will be blinded.
The device will stay on the patient up to 5 days, or until discharge from the ICU.
|
Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
|---|
|
Number of severe hyperglycaemias and hypoglycaemias with blood glucose levels >25 mmol/l and <2.2 mmol/l
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
死亡
|
||
|
Length of stay in the ICU
|
||
|
Time duration that the blood glucose levels of a patient are within the 'target range' (measured with the freestyle Navigator®)
|
The target range in the ICU of the OLVG is set between 5 and 9 mmol/l according to the local treatment protocol
|
|
|
Time duration that the blood glucose levels of a patient are under and above the 'target range' (measured with the freestyle Navigator®)
|
The target range in the ICU of the OLVG is set between 5 and 9 mmol/l according to the local treatment protocol
|
|
|
- Variability of the glycemic levels by arterial measuring with the blood gas analyzer (BGA), determined by the Mean Absolute Glucose change per hour (MAG)
|
Mean Absolute Glucose change per hour: ΔBGA / Δtime The MAG is calculated by taking the sum of all absolute glucose changes during admission (measured by BGA) and dividing this by the total time spent in the ICU in hours. |
|
|
False positive frequency of alarms of the Freestyle Navigator®
|
Verified by the glucose level measurements by blood gas analyzer
|
|
|
Number of undesirable low glucose levels per 24 hours
時間枠：24 hours
|
blood glucose levels between 2,5 and 5 mmol/l
|
24 hours
|
|
Number of missed hypoglycemia's with the AccuChek (measured with the Freestyle Navigator®)
|
||
|
Number of blood samples per day
時間枠：24 hours
|
24 hours
|
協力者と研究者
捜査官
- 主任研究者：P HJ van der Voort, MD, PhD、Onze Lieve Vrouwe Gasthuis
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Freestyle Navigatorの臨床試験
-
University Medical Centre LjubljanaKarolinska Institutet; Schneider Children's Medical Center, Israel完了
-
Abbott Diabetes CareLiverpool University Hospitals NHS Foundation Trust; NHS Lothian; Cardiff and Vale University... と他の協力者完了
-
Stanford UniversitySanta Clara Valley Health & Hospital System完了
-
University of PennsylvaniaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)完了
-
Palo Alto Medical FoundationEmory University; Abbott Diabetes Care募集
-
University of California, RiversideNational Institute of Mental Health (NIMH); University of California, Los Angeles; University...まだ募集していませんうつ | 不安 | メンタルヘルスの問題
-
Pain ConcernThe Thistle Foundation; Health and Social Care Alliance Scotland (the ALLIANCE); Edinburgh and...完了慢性の痛み | 慢性疼痛症候群 | 慢性痛、広範囲 | 外傷による慢性疼痛 | 悪性腫瘍による慢性疼痛（所見） | けがによる慢性的な痛み | 慢性疼痛 処置後 | 慢性痛 股関節イギリス